A detailed history of Huntington National Bank transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Huntington National Bank holds 1 shares of AUTL stock, worth $2. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Previous 1 -0.0%
Holding current value
$2
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$1.64 - $3.21 $2,460 - $4,815
-1,500 Reduced 99.93%
1 $0
Q4 2021

Jan 21, 2022

BUY
$5.1 - $7.0 $7,655 - $10,507
1,501 New
1,501 $8,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $208M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Huntington National Bank Portfolio

Follow Huntington National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.